Donanemab for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 10 registered trials.

Why this status

  1. 18 Jun 2020: Trial registered, NCT04437511
  2. 19 Jun 2020: Trial started, NCT04437511
  3. 5 Nov 2021: Trial registered, NCT05108922
  4. 16 Nov 2021: Trial started, NCT05108922
  5. 19 Aug 2022: Trial registered, NCT05508789
  6. 10 Oct 2022: Trial started, NCT05508789
  7. 22 May 2026: Trial registered, NCT07602582
  8. 22 May 2026: Trial started, NCT07602582

The trials

NCT03367403: A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

State
Completed
Phase
Phase 2
People
272 taking part
Started
18 Dec 2017
Primary completion
4 Dec 2020
Arms
Donanemab Monotherapy (Donanemab-M)
Results
Posted on the registry
  1. 8 Dec 2017: Trial registered
  2. 18 Dec 2017: Trial started
  3. 21 Sep 2021: Trial completed
  4. 15 Feb 2022: Trial results posted

NCT04437511: A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

State
Under way
Phase
Phase 3
People
1,736 taking part
Started
19 Jun 2020
Primary completion
14 Apr 2023
Arms
Donanemab
Results
Posted on the registry
  1. 18 Jun 2020: Trial registered
  2. 19 Jun 2020: Trial started
  3. 20 May 2024: Trial results posted

NCT04640077: A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

State
Completed
Phase
Phase 2
People
95 taking part
Started
23 Nov 2020
Primary completion
27 Feb 2024
Arms
Part B: Donanemab
Results
Posted on the registry
  1. 23 Nov 2020: Trial registered
  2. 23 Nov 2020: Trial started
  3. 27 Feb 2024: Trial completed
  4. 13 Jun 2025: Trial results posted

NCT05108922: A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

State
Completed
Phase
Phase 3
People
148 taking part
Started
16 Nov 2021
Primary completion
9 Sep 2022
Arms
Donanemab
Results
Posted on the registry
  1. 5 Nov 2021: Trial registered
  2. 16 Nov 2021: Trial started
  3. 19 Sep 2023: Trial completed
  4. 2 Nov 2023: Trial results posted

NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

State
Under way
Phase
Phase 3
People
1,500 planned
Started
10 Oct 2022
Primary completion
May 2028
Arms
Donanemab
Results
None posted
  1. 19 Aug 2022: Trial registered
  2. 10 Oct 2022: Trial started

NCT06911944: Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation

State
Not started
Phase
Phase 4
People
60 planned
Started
1 Aug 2026
Primary completion
31 Dec 2028
Arms
donanemab
Results
None posted
  1. 4 Apr 2025: Trial registered

NCT06996730: A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease

State
Under way
Phase
Phase 2 and Phase 3
People
240 planned
Started
8 Jul 2026
Primary completion
1 Jun 2030
Arms
Part 1: Donanemab, Part 2: Donanemab + RG6289 placebo
Results
None posted
  1. 30 May 2025: Trial registered
  2. 8 Jul 2026: Trial started

NCT07589595: A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

State
Under way
Phase
Phase 2
People
350 planned
Started
20 May 2026
Primary completion
Aug 2028
Arms
Donanemab (LY3002813)
Results
None posted
  1. 15 May 2026: Trial registered
  2. 20 May 2026: Trial started

NCT07602582: A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

State
Under way
Phase
Phase 3
People
550 planned
Started
22 May 2026
Primary completion
Sep 2029
Arms
Donanemab
Results
None posted
  1. 22 May 2026: Trial registered
  2. 22 May 2026: Trial started

NCT07838155: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

State
Not started
Phase
Phase 4
People
50 planned
Started
Nov 2026
Primary completion
Sep 2030
Arms
Donanemab
Results
None posted
  1. 24 Sep 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.